Skip to content
Nakoda News
The Brief
Binance Aims to Reopen All Withdrawals by Next Week After $6.3 Billion HackSpinneys Absorbs Up to Fourfold Freight Costs to Keep UAE Shelves StockedBlackstone's AirTrunk Signs MoU for 1.8GW of Data Centres in India's Andhra PradeshJulphar's Nine-Month Profit From Continuing Operations Jumps to AED 89 MillionRunway Releases Open Weights for Praxis-1, Its Video-Trained Robot Control ModelChinese Open-Weight Models Show Signs of Training on Banned Nvidia Blackwell ChipsOpenAI Raises $15 Billion at $1.25 Trillion Valuation, Half Its Original TargetSaudi AI Start-Up Shaffra Says Its Digital Employees Saved Clients 800,000 Work Hours
Companies

Julphar's Nine-Month Profit From Continuing Operations Jumps to AED 89 Million

The Ras Al Khaimah drugmaker lifted revenue 13.5% to AED 906 million, though total net profit fell against a 2025 period boosted by a one-off disposal gain.

By Nakoda News Desk

·2 min read

Prefer Nakoda News on Google

Gulf Pharmaceutical Industries, known as Julphar, made a net profit from continuing operations of AED 89 million in the first nine months of 2026, up from AED 8.1 million a year earlier, as sales and margins improved in its main markets, according to results reported by Al Bayan.

Revenue from continuing operations rose 13.5% to AED 906 million, from AED 797.9 million. Gross profit climbed 23.5% to AED 394.3 million, and earnings before interest, tax, depreciation and amortisation rose 90.3% to AED 126 million from AED 66.2 million.

The figures show a turnaround at the Ras Al Khaimah-based company, which finished restructuring its debt in 2025. Headline profit tells a different story, however. Total net profit fell to AED 87.5 million from AED 138.2 million, because the 2025 period included a one-off capital gain of AED 118.7 million from the sale of Zahrat Al Rawda Pharmacies.

The company said part of the revenue growth came from shifts in when sales were booked between quarters after regional geopolitical disruption, as well as some non-recurring sales. Excluding those effects, underlying growth was 6.4%. It said a better product mix, more diverse suppliers and efficiency measures helped offset higher costs for raw materials and logistics and disruption to supply chains.

Sales in international markets outside the Gulf grew fastest, up 28.6% to AED 335 million. UAE revenue rose 9% to AED 340.7 million, and sales in other GCC countries rose 2.4% to AED 230.3 million.

On the balance sheet, loans and other interest-bearing liabilities stood at AED 263.8 million at the end of September. Total equity rose to AED 1.0469 billion from AED 959.8 million at the end of December 2025, and accumulated losses narrowed to AED 74 million from AED 163 million at the start of the year.

Julphar launched four new medicines in the UAE during the period and completed 27 product registrations in international markets. Capital spending was AED 27.3 million. Chief executive Basel Ziadeh said the company would keep expanding its drug portfolio and investing in manufacturing capacity.

The company is still building a new manufacturing plant in Saudi Arabia, and it plans to add selected biotechnology and specialty medicines to its pipeline.

Sources

  • البيان · «جلفار» ترفع إيراداتها 13.5% وأرباحها التشغيلية 90.3% خلال 9 أشهر

Produced with AI assistance from the sources above. How we work

TagsCompaniesFinanceHealthcareManufacturingUAEGCC

By

Nakoda News Desk

Nakoda News covers AI and business. Every story links the sources it draws on; how we work is set out in our editorial standards.

How we work

Related coverage